EU schizophrenia guidance highlights unmet needs
This article was originally published in Scrip
Executive Summary
The European Medicines Agency's new guidelines on developing schizophrenia treatments now include recommendations on R&D that targets the condition's traditionally overlooked negative and cognitive symptoms. The guidelines are encouraging because they highlight areas of unmet need, but developmental challenges mean they will not "translate into the launch of marketed products in the mid-term", said Charlotte Mackey, a lead analyst at Datamonitor.
You may also be interested in...
Can Biosimilar Orphans Increase Health System Sustainability In The UK?
Developing biosimilar orphan drugs is fraught with challenges and needs buy-in from regulators, developers, patients and clinicians.
Brazil Authorizes Oxford/AZ and Sinovac Vaccines
In addition to agreeing to emergency use of the Oxford University/Astra Zeneca and Sinovac vaccines, Brazil's medicines regulator has also published good manufacturing practices certificates for Pfizer and Janssen vaccine. It has questions about the Sputnik V authorization request.
Success For Dutch Parallel Registration and Reimbursement Pilot
A Dutch parallel registration and reimbursement pilot has brought benefits including more participation from healthcare professionals, and also forces company divisions to be less streamlined.
Need a specific report? 1000+ reports available
Buy Reports